---
layout: default
title: Trametinib
parent: Low Evidence (L5)
nav_order: 1000
evidence_level: L5
indication_count: 10
---

# Trametinib
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Trametinib: From BRAF-Mutant Melanoma to Choroideremia

## One-Sentence Summary

Trametinib is an oral MEK inhibitor that is marketed in Singapore and used in BRAF-mutant melanoma, although the registry records supplied here leave the approved-indication text blank.
The TxGNN model predicts it may be effective for **choroideremia**, an inherited retinal degeneration.
**No clinical trials and no publications** currently support this prediction, so it rests on the model score alone.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the supplied registry data (all licences have blank indication text); the trial evidence for the drug concerns BRAF V600-mutant melanoma |
| Predicted New Indication | Choroideremia |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Trametinib is known as a MEK1/MEK2 inhibitor, and its efficacy has been established in BRAF V600-mutant melanoma, usually combined with dabrafenib. This means it acts on the MAPK signalling pathway.

Choroideremia is an X-linked retinal degeneration caused by loss of the CHM/REP1 gene. The supplied data show no plausible link between choroideremia and MEK/MAPK signalling, and the pack's own assessment is that the very high score is likely a knowledge-graph artifact rather than a true mechanistic signal. This prediction should therefore be treated as a hypothesis only. No similarity analysis between the original and new indication is available.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Singapore Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| SIN15182P | MEKINIST FILM-COATED TABLETS 2MG | Film-coated tablet | Not stated in registry data |
| SIN15181P | MEKINIST FILM-COATED TABLETS 0.5MG | Film-coated tablet | Not stated in registry data |
| SIN17018P | MEKINIST POWDER FOR ORAL SOLUTION 4.7 MG | Powder for oral solution | Not stated in registry data |

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (MEK inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

## Safety Considerations

Please refer to the package insert for safety information. No drug interaction records were found in the supplied data.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has no supporting trials or literature, and no mechanistic link between MEK/MAPK inhibition and choroideremia is evident. The high score is most likely a graph artifact, and safety data are also missing.

**To proceed, the following is needed:**
- Mechanistic evidence connecting MEK/MAPK signalling to CHM/REP1-deficient retinal degeneration, such as preclinical retinal models
- Detailed mechanism of action data (MOA) from DrugBank
- HSA package insert warnings and contraindications, which are currently a blocking gap
- The approved indication text for the Singapore registrations, to confirm the original indication
- Assessment of route compatibility, since an ocular disease may need a different delivery route from the oral forms registered

**Note:** Other predictions for this drug have stronger support, all in melanoma subtypes. Non-cutaneous melanoma is at L2 and nodular melanoma is at L3 with "Proceed with Guardrails". These are better candidates for further evaluation than choroideremia.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

